Practical guides for physicians, NPs, PAs and nurses on IV therapy, peptides, regenerative medicine and the business of practicing beyond insurance.

The peptide shift hasn't changed FDA rules for stem cells or exosomes. What's approved, what's not, and the compliance checklist for clinicians.

What FDA's interim peptide compounding policy and the July PCAC vote actually change for your practice, and what's still not legal to compound.